<DOC>
	<DOC>NCT01688024</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness and safety of mitomycin C in the treatment of primary sclerosing cholangitis (PSC).</brief_summary>
	<brief_title>Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis, Sclerosing</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Ages 18 or older Previously established diagnosis of primary sclerosing cholangitis American Society of Anesthesiologists class 4 or greater Serum creatinine &gt;= 1.7 mg/dL, eGFR &lt;= 30 mL/min, or dialysis dependence Serum hemoglobin &lt;= 7 g Left ventricular ejection fraction &lt;= 30% Dyspnea with minimal exertion (or supplemental oxygen dependence) History of bone marrow disease Prior recipient of organ transplantation Ongoing chemotherapy Obstruction of the upper GI tract Pregnant or lactating Inability to provide informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>mitomycin C</keyword>
</DOC>